ANDERSON David W.
No ORCID on file
· 20 papers in corpus
· active 2000-2001
Frequent coauthors
- BHAGWAT Shripad S. 20
- DOUBLEDAY Mary 20
- GAYO Leah M. 20
- JALLURI Ravi Kumar 20
- KOIS Adam 20
- KHAMMUNGKHUNE Sak 20
- MCKIE Jeffrey A. 20
- SHEVLIN Graziella I. 20
- STEIN Bernd M. 20
- SUTHERLAND May S. 20
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…